We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Hiddo Heerspink PhD

Hiddo L. Heerspink PhD

Professor of Medicine, University of Groningen, University Medical Center Groningen, Groningen Netherlands

Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen. He is also visiting professor at the University of New South Wales in Sydney. He studied pharmacy at the University of Groningen and received his PhD from the University Medical Center Groningen.

Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of kidney and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He leads numerous clinical trials with new interventions to reduce diabetes related kidney and cardiovascular complications. His main expertise includes clinical trial design, personalized medicine and methodological aspects and statistical analyses of clinical trials.

Professor L. Heerspink has authored and co-authored over 350 peer-reviewed publications and is editorial board member of Diabetes Obesity and Metabolism and the Clinical Journal of the American Society of Nephrology. Prof L. Heerspink is a consultant and has received honoraria from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Pharma, Chinook, Dimerix, Janssen, Fresenius, Gilead, Merck, Mitsubishi Tanabe, Mundi Pharma, NovoNordisk and Travere Pharmaceuticals.


Prof. Heerspink reports the following:
  • Grants/contracts (payments to institution): AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk
  • Consulting fees (payments to institution):  AstraZeneca, Abbvie, Boehringer Ingelheim, CSL Behring, Bayer, Chinook, Dimerix, Gilead, Goldfinch, Merck, Novartis, NovoNordisk, Janssen,  Traveere Pharmaceuticals
  • Payment/honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (payments to institution/self): AstraZeneca